BLOOMFIELD, N.J., July 10 /PRNewswire-FirstCall/ -- Alfacell Corporation , a biopharmaceutical company focused on the discovery, development and commercialization of novel ribonuclease (RNase) therapeutics for cancer and other life-threatening diseases, today announced that Andrew Aromando, Senior Vice President, Commercial Development and Operations, is scheduled to present at the C.E. Unterberg, Towbin Emerging Growth Opportunities Conference at The Mandarin Oriental Hotel in New York at 1:44 PM EDT on Wednesday, July 12. The presentation will be accessible live via Wall Street Webcasting at http://www.wsw.com/webcast/ceut4/acel, and will be available for replay.
Alfacell is one of 42 invited companies scheduled to present in the Biotechnology, Medical Devices, and Specialty Pharmaceuticals sector of the conference. For more information, please visit http://www.unterberg.com.
About Alfacell Corporation
Alfacell Corporation is a biopharmaceutical company focused on the discovery, development and commercialization of novel therapeutics for cancer and other diseases, using its ribonuclease (RNase) technology platform. ONCONASE(R) (ranpirnase), Alfacell's lead investigational drug candidate, is currently being evaluated in several studies, including a Phase IIIb registration study for unresectable malignant mesothelioma (UMM). The Company has developed and managed one of the largest UMM clinical programs ever undertaken, with over 600 patients enrolled, including newly-diagnosed and refractory patients treated with ONCONASE as a single agent and in combination with doxorubicin. A Phase I / II trial evaluating ONCONASE in non-small cell lung cancer (NSCLC) is also in progress. For more information, please visit http://www.alfacell.com.
This press release includes statements that may constitute "forward- looking" statements, usually containing the words "believe," "estimate," "project," "expect" or similar expressions. Forward-looking statements involve risks and uncertainties that could cause actual results to differ materially from the forward-looking statements. Factors that would cause or contribute to such differences include, but are not limited to, uncertainties involved in transitioning from concept to product, uncertainties involving the ability of the Company to finance research and development activities, potential challenges to or violations of patents, uncertainties regarding the outcome of clinical trials, the Company's ability to secure necessary approvals from regulatory agencies, dependence upon third-party vendors, and other risks discussed in the Company's periodic filings with the Securities and Exchange Commission. By making these forward-looking statements, the Company undertakes no obligation to update these statements for revisions or changes after the date of this release.
Contact: Alfacell Corporation: Investor/Media Relations: Kuslima Shogen Elite Financial Communications Robert Love Dodi Handy (973) 748-8082 (407) 585-1080 info@alfacell.comacel@efcg.net
Alfacell CorporationCONTACT: Kuslima Shogen or Robert Love, both of Alfacell Corporation,+1-973-748-8082, info@alfacell.com; or Investor\Media Relations: Dodi Handyof Elite Financial Communications, +1-407-585-1080, acel@efcg.net, forAlfacell Corporation
